Grainne Donnellan
Vancouver, BC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 01, 2025
Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 26, 2025
Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.
Journal: European urology oncology
Published: April 30, 2025
Clonal hematopoiesis in metastatic urothelial and renal cell carcinoma.
Journal: NPJ precision oncology
Published: January 17, 2025
ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 21, 2024
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.
Journal: Nature medicine
Published: November 05, 2024
Plasma Cell-Free DNA Chromatin Immunoprecipitation Profiling Depicts Phenotypic and Clinical Heterogeneity in Advanced Prostate Cancer.
Journal: Cancer research
Published: June 20, 2024
Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 28, 2022
Showing 1-10 of 10
Last Updated: 09/26/2026